BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Novartis Combo could be New Standard of Care for Pediatric Glioma Patients

  Results of a Phase II/III study showed that patients who were given Tafinlar plus Mekinist saw an overall response rate of 47% vs. 11% for those who received standard chemotherapy only.

  June 7, 2022

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Policy

  bluebird bio Blazes Trail for Lentiviral Vectors at Upcoming FDA Meeting

  For the first time in half a decade, the FDA will convene to address two therapies developed by bluebird bio that could have ripple effects across the industry regarding lentiviral vectors.

  June 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Novavax on the Verge as FDA Adcom Recommends COVID-19 Vaccine

  On Tuesday, the FDA’s Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention to recommend authorization of Novavax’s COVID-19 vaccine.

  June 7, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Sernova Cell Pouch Keeps T1 Diabetes Patient Insulin Free for 2 Years

  Sernova shared positive Phase I/II data from an ongoing clinical study of its implantable Cell Pouch device that showed evidence of in vivo active insulin production.

  June 7, 2022

   · 

  4 min read

   · 

  Alex Keown
• 

  Drug Development

  Merck Predicts Over 80 Potential Oncology Approvals Through 2028

  Powered by its blockbuster checkpoint inhibitor Keytruda, Merck is forecasting a potential of more than 80 new regulatory approvals in oncology through 2028.

  June 7, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Lilly’s Mounjaro Bests Novo’s Diabetes Drugs in Comparison Study

  The Phase I mechanism of action study, showing that Lilly’s injectable Mounjaro (tirzepatide) induces greater weight loss than placebo and Novo Nordisk’s semaglutide in adults with type 2 diabetes.

  June 7, 2022

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Amarin, Vincerx Cut Jobs in Effort to Extend Cash Flow

  Amarin and Vincerx Pharma intend to restructure their financial strategies and lessen operational costs by trimming their employee rosters.

  June 7, 2022

   · 

  2 min read

   · 

  Jazmine Colatriano
• 

  Business

  Aslan, Yumanity, Editas, Janssen and More Team Up to Fight Disease

  Aslan partners with Johns Hopkins and Duke, Editas joins forces with Immatics, Yumanity (soon to be Kineta, Inc.) teams with Janssen, Serotiny & Janssen Biotech and Ginkgo and Novo Nordisk.

  June 7, 2022

   · 

  4 min read

   · 

  Hannah Chudleigh
• 

  Drug Development

  Research Shows Stem Cells Might Become a Game Changer for Multiple Sclerosis

  The Tisch MS Research Center of New York has been researching the concept of using cell therapy as a therapeutic strategy to promote repair and regeneration in certain patients with MS.

  June 7, 2022

   · 

  7 min read

   · 

  Kaley Lefevre
• 

  Drug Development

  CEL-SCI, Jazz, CARsgen, Ascentage and Portage Showcase New Data at ASCO

  CEL-SCI Corporation, Jazz Pharmaceuticals, CARsgen and Ascentage Pharma presented clinical trial data at the American Society of Clinical Oncology 2022 Annual Meeting.

  June 7, 2022

   · 

  4 min read

   · 

  Mark Terry